South America Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Users (hospitals clinics, diagnostic centers, academic research institutes)-Forecast to 2035

South America Dry Age-Related Macular Degeneration (AMD) Market Overview

As per MRFR analysis, the South America Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 440.0 (USD Million) in 2023. The South America Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 480.0(USD Million) in 2024 to 1,095.0 (USD Million) by 2035. The South America Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 7.786% during the forecast period (2025-2035).

Key South America Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted

The South America Dry Age-Related Macular Degeneration (AMD) market is experiencing notable trends driven largely by the increasing aging population within the region. Countries like Brazil and Argentina are witnessing a rise in elderly individuals, leading to a higher prevalence of age-related eye diseases. Additionally, awareness campaigns focused on the importance of early diagnosis and prevention are gaining traction. These initiatives are supported by both government health organizations and non-profit groups aiming to educate the public about AMD and its management. Opportunities in the South America Dry AMD market are being explored as there is a growing interest among pharmaceutical companies to develop innovative therapies and advanced treatment options tailored for the regional demographics.

The need for efficient anti-AMD treatments will require investment in research and development. Specialists targeting low-serviced locations have a tremendous opportunity if they are willing to tackle the challenges posed by local healthcare systems. The trends show that personalized medicine is starting to penetrate into the market. There is an increasing acceptance by doctors of a move towards bespoke treatment regimens driven by the patient's genetic makeup and their way of living. In addition, the use of digital health services like telemedicine and health for monitoring and treatment of AMD is growing, especially in areas where specialists are scarce.

Given the diverse population and varied healthcare challenges in South America, these developments are crucial in addressing the unique needs of patients suffering from Dry AMD in the region.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

South America Dry Age-Related Macular Degeneration (AMD) Market Drivers

Increasing Aging Population

The South America Dry Age-Related Macular Degeneration (AMD) Market Industry is significantly driven by the increasing aging population in the region. Data from regional demographic studies indicate that the population aged 65 and older in South America is projected to rise from approximately 9% in 2020 to about 13% by 2035. This demographic shift is driven by improved healthcare access and life expectancy. Organizations like the Pan American Health Organization (PAHO) have highlighted the need for enhanced healthcare systems to support the growing number of elderly individuals, many of whom are at higher risk for age-related conditions such as AMD.Consequently, the rising aged demographic is expected to lead to a greater demand for AMD-related healthcare solutions and treatments, subsequently propelling market growth in the coming years. As the healthcare system evolves to meet these needs, the South America Dry Age-Related Macular Degeneration (AMD) Market is predicted to expand.

Increased Awareness and Screening Programs

In South America, there has been a notable increase in public awareness regarding eye health, particularly related to dry AMD. Various public health campaigns and initiatives spearheaded by healthcare authorities and organizations are promoting early detection and regular eye screenings. For instance, the Brazilian Ministry of Health has launched programs aimed at educating the public on the risks of AMD and the importance of regular eye examinations, which is projected to increase screenings by over 30% in the next five years.This rise in screenings will likely lead to earlier diagnoses, driving demand for AMD treatments and resources in the South America Dry Age-Related Macular Degeneration (AMD) Market Industry.

Advancements in Treatment Options

The South America Dry Age-Related Macular Degeneration (AMD) Market is experiencing growth fueled by advancements in treatment options. Novel therapies, such as anti-VEGF injections and nutritional supplements like AREDS formulations, are being increasingly introduced in the region. Research from pharmaceutical organizations indicates that innovative treatments may reduce the progression of AMD by over 25% when started early. The Brazilian Society of Ophthalmology has emphasized the importance of adopting these advanced treatment protocols in clinical practice.As healthcare providers become more equipped to offer these treatments, the demand in the South America Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to rise in response.

South America Dry Age-Related Macular Degeneration (AMD) Market Segment Insights

Dry Age-Related Macular Degeneration (AMD) Market Stage Insights

The South America Dry Age-Related Macular Degeneration (AMD) Market is witnessing substantial growth, driven by the increasing prevalence of age-related eye diseases among the aging population. Within the market, the Stage segment plays a pivotal role, as it encompasses various classifications of AMD that determine the severity and treatment approaches. Early age-related macular degeneration is often characterized by subtle vision changes and is critical for intervention strategies, as early diagnosis can lead to better management and improved quality of life for patients. This segment is essential in the realm of preventive care, emphasizing regular eye examinations for the elderly population. Intermediate age-related macular degeneration tends to show more pronounced symptoms, including blurred vision or difficulty in recognizing faces.

This stage represents a significant focus for healthcare professionals, as it signals a transition to more severe deterioration and highlights the urgency for effective therapeutic measures. Innovative treatment options are continually emerging in this space, aiming to slow down the progression of the disease. Late age-related macular degeneration is particularly concerning, as it affects a substantial part of the visual field and can lead to irreversible vision loss. This stage is crucial in understanding the broader implications for public health, as it increases the burden on healthcare systems and impacts the quality of life for numerous patients.

As a result, the South America Dry Age-Related Macular Degeneration (AMD) Market is poised to develop new therapies and preventive measures. Overall, the Stage segment's insights are foundational for developing targeted strategies and treatments, demonstrating the critical need for awareness and research in addressing AMD across different age groups in South America.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights

The Age Group segment within the South America Dry Age-Related Macular Degeneration (AMD) Market showcases significant insights into the demographics affected by this condition. Individuals above 75 years represent a critical population due to the higher prevalence of AMD in older adults, often serving as a focal point for healthcare resources and treatments. This age group is increasingly recognizing the importance of early diagnosis and management of AMD, which drives market demand for innovative therapeutic options. The demographic above 60 years also plays a vital role, as awareness campaigns are prevalent in this bracket, which continues to grow due to the aging population in South America.

The above 40 years age group is emerging prominently with a rising incidence of early AMD manifestations, leading to early intervention strategies and preventive measures gaining traction. The market growth in South America is particularly influenced by an increased life expectancy, which correlates with a higher number of individuals experiencing age-related eye conditions. Overall, the Age Group segmentation reveals critical behavioral trends, challenges, and opportunities that shape the South America Dry Age-Related Macular Degeneration (AMD) Market industry.

Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights

The Diagnosis and Treatment segment of the South America Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in addressing this prevalent condition that significantly impacts vision among the aging population. The emphasis on early diagnosis is essential, as timely detection can lead to effective management and improved patient outcomes. The market for treatment options is expanding rapidly, driven by the increasing incidence of dry AMD, which is associated with significant visual impairment and a declining quality of life. Innovations in treatment methods, including advanced pharmaceuticals and laser therapies, are shaping the market landscape.Countries in South America are witnessing a rising awareness and education regarding AMD, which contributes to growth within this segment. Moreover, collaborations between healthcare providers and research institutions are enabling the development of more effective diagnostic tools and treatment protocols.

However, challenges such as access to healthcare facilities and affordability of treatments remain pertinent. Nonetheless, growing investment in healthcare infrastructure poses considerable opportunities for expanding the reach of diagnosis and treatment solutions, improving overall market dynamics in the region.As the population ages, the significance of this segment in the South America Dry Age-Related Macular Degeneration (AMD) Market is set to increase, reflecting an ongoing commitment to improving eye health for millions.

Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights

The Route of Administration segment within the South America Dry Age-Related Macular Degeneration (AMD) Market is crucial as it influences the effectiveness and patient adherence to treatment modalities. This market segment showcases a significant division between oral therapies and injectable treatments. Oral administration is valued for its convenience and ease of use, appealing particularly to the older demographic often affected by AMD, while injectables are acknowledged for delivering medications more directly and efficiently to the eye, thereby enhancing therapeutic outcomes.As the population continues to age, the demand for effective and user-friendly treatment options in South America is expected to grow, fostering innovations in drug formulations and delivery mechanisms.

This evolving landscape is driven by the rising prevalence of AMD and the urgent need for effective management solutions. Regulatory frameworks and healthcare infrastructure improvements further support the expansion of this market segment, aligning with regional health initiatives aimed at improving eye health and reducing the burden of visual impairment.Such dynamics enable the Route of Administration segment to play a pivotal role in addressing the needs of AMD patients and contribute significantly to the overall market’s growth potential.

Dry Age-Related Macular Degeneration (AMD) Market End Users Insights

The South America Dry Age-Related Macular Degeneration (AMD) Market showcases a diverse array of end users, significantly shaping its landscape. Hospitals and clinics serve as primary facilitators, providing direct patient care and essential treatment protocols that cater to the rising prevalence of AMD in the aging population, estimated at around 13% in South America, thus highlighting their pivotal role in the healthcare system. Diagnostic centers contribute by facilitating early detection through advanced imaging technologies, enabling timely interventions that can slow disease progression.Their emphasis on accurate diagnostics directly influences patient outcomes, which is increasing demand for such specialized services.

Furthermore, academic and research institutes are crucial for cultivating innovative treatment approaches and training healthcare professionals in the region. The growing investment in research reflects a commitment to addressing AMD challenges while also fostering collaborations that enhance the overall medical expertise available in South America. Each of these end users plays a significant role in the AMD market ecosystem, collectively driving advancements that improve patient care and health outcomes within the region.

South America Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights

The South America Dry Age-Related Macular Degeneration (AMD) Market presents a dynamic and competitive landscape characterized by various players striving to address the growing prevalence of AMD in the region. Market insights reveal that several companies are focusing on enhancing treatment options through innovative research and development efforts. As the population ages and awareness about eye health increases, demand for effective solutions to manage AMD is expected to rise significantly. This trend drives companies to create specialized products targeting AMD management, incorporating advanced technology and novel therapeutics. The competition is not only among pharmaceutical giants but also includes emerging firms seeking to carve a niche in this vital therapeutic area.

Companies involved in this market are compelled to improve their service delivery, product effectiveness, and patient outcomes to maintain a competitive edge.Bayer has positioned itself as a strong player in the South America Dry Age-Related Macular Degeneration (AMD) Market, driven by its commitment to research and development as well as its robust marketing strategies. The company's expertise in ophthalmology is reflected in its innovative product offerings tailored to meet the specific needs of the South American demographic. Bayer's established presence in the region allows for a more profound understanding of local healthcare practices and regulatory frameworks. With a well-distributed network and partnerships with healthcare providers, Bayer ensures that its treatments reach patients effectively.

The company's focus on patient education and awareness campaigns further strengthens its position in the market, enabling them to connect better with the communities they serve.Genentech, recognized for its pioneer work in biopharmaceuticals, has made significant inroads into the South America Dry Age-Related Macular Degeneration (AMD) Market. The company's emphasis on groundbreaking therapies, particularly in areas of retinal diseases, positions it favorably against competitors. Genentech's portfolio includes key products designed specifically for AMD management, which enhance patient outcomes while focusing on safety and efficacy. The company's presence is bolstered by strategic mergers and acquisitions that expand its capabilities and enhance its research infrastructure within the region.

By leveraging local partnerships and relationships with health providers, Genentech ensures that its offerings are accessible to patients in South America, thereby improving health outcomes. Their commitment to understanding regional medical needs drives the development of targeted therapies that reflect the evolving landscape of AMD treatment in South America.

Key Companies in the South America Dry Age-Related Macular Degeneration (AMD) Market Include

• Bayer


• Genentech


• Valeant Pharmaceuticals


• Zeiss


• Allergan


• Roche


• Ophthotech


• Opthea


• Fovea Pharmaceuticals


• Novartis


• Santen Pharmaceutical


• Eyenovia


• Regeneron Pharmaceuticals


• Apellis Pharmaceuticals

South America Dry Age-Related Macular Degeneration (AMD) Market Industry Developments

Recent developments in the South America Dry Age-Related Macular Degeneration (AMD) Market have been significant as companies like Bayer, Genentech, and Novartis continue to focus on innovative treatment solutions. In August 2023, Bayer launched a new initiative aimed at increasing awareness and diagnosis of AMD in the region, particularly in Brazil and Argentina, where incidence rates are markedly high. Additionally, Roche's commitment to research and development has led to promising clinical trials for new therapies targeting dry AMD, showcasing their potential to enhance patient outcomes. In terms of mergers and acquisitions, Novartis announced in July 2023 their acquisition of a smaller biotech firm focused on ocular treatments, which is anticipated to strengthen its portfolio within the AMD sector.

Over the past couple of years, there has been notable growth in market valuation as investments in AMD treatment technologies have surged, reflecting increasing demand for effective therapies. This growth trend has been particularly evident in countries with aging populations, such as Chile and Uruguay, further driving interest from pharmaceutical companies and investors alike.

South America Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights

• Dry Age-Related Macular Degeneration (AMD) MarketStageOutlook


• early age-related macular degeneration


• intermediate age-related macular degeneration


• late age-related macular degeneration


• Dry Age-Related Macular Degeneration (AMD) MarketAge GroupOutlook


• above 75 years


• above 60 years


• above 40 years


• Dry Age-Related Macular Degeneration (AMD) MarketDiagnosis and TreatmentOutlook


• treatment


• diagnosis


• Dry Age-Related Macular Degeneration (AMD) MarketRoute of AdministrationOutlook


• oral


• injectables


• Dry Age-Related Macular Degeneration (AMD) MarketEnd UsersOutlook


• hospitalsclinics


• diagnostic centers


• academicresearch institutes

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	440.0(USD Million)
MARKET SIZE 2024	480.0(USD Million)
MARKET SIZE 2035	1095.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.786% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Bayer, Genentech, Valeant Pharmaceuticals, Zeiss, Allergan, Roche, Ophthotech, Opthea, Fovea Pharmaceuticals, Novartis, Santen Pharmaceutical, Eyenovia, Regeneron Pharmaceuticals, Apellis Pharmaceuticals
SEGMENTS COVERED	Stage, Age Group, Diagnosis and Treatment, Route of Administration, End Users
KEY MARKET OPPORTUNITIES	Rising geriatric population, Increased awareness and education, Development of innovative therapies, Expansion of telemedicine services, Strengthening healthcare infrastructure
KEY MARKET DYNAMICS	increasing elderly population, rising healthcare expenditure, advancements in treatment options, growing awareness and diagnosis, expanding pharmaceutical investments
COUNTRIES COVERED	Brazil, Mexico, Argentina, Rest of South America